Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Chicago
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
Ossium Health, Inc.
St. Jude Children's Research Hospital
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
University of Arizona
M.D. Anderson Cancer Center
University of Miami
Thomas Jefferson University
Thomas Jefferson University
National Institutes of Health Clinical Center (CC)
Affimed GmbH
European Organisation for Research and Treatment of Cancer - EORTC
Massachusetts General Hospital
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
Thomas Jefferson University
City of Hope Medical Center
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Instituto Nacional de Cancer, Brazil
Baylor College of Medicine
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
University of Cologne
Roswell Park Cancer Institute
University College, London
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Baylor College of Medicine
Martin-Luther-Universität Halle-Wittenberg
University of Nebraska
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
University of Birmingham
St. Jude Children's Research Hospital
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Northside Hospital, Inc.
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Thomas Jefferson University